Recent Offering Announcement by Aquestive Therapeutics
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a forward-thinking pharmaceutical company dedicated to enhancing patients' lives through advanced medicine and innovative delivery technologies, has announced the pricing details of its recent underwritten offering. This offering entails 21,250,000 shares of common stock, priced at $4.00 per share. The offering is set to generate gross proceeds amounting to $85 million, before accounting for underwriting discounts, commissions, and other related expenditures.
Use of Proceeds from the Offering
The company intends to utilize the net proceeds to foster the launch and commercialization of its product Anaphylm™ (epinephrine) Sublingual Film, intended to treat severe allergic reactions, including life-threatening anaphylaxis. The success of this launch depends on the approval from the United States Food and Drug Administration (FDA). Additionally, the proceeds are planned for use in working capital, capital expenditures, and general corporate initiatives.
Details of the Offering
Leading the offering are seasoned firms RTW Investments, LP along with participation from renowned investment groups such as Samsara BioCapital, EcoR1 Capital, Perceptive Advisors, Sio Capital Management, ADAR1 Capital Management, and Nantahala Capital. The sale of securities is solely managed by the company itself. The anticipated closing date for this offering is on or around August 15, 2025, contingent upon the fulfillment of standard closing procedures.
Management and Initial Steps for Commercialization
The capital raised will not only empower Aquestive in its current endeavors but also allow continued development in their pipeline. The firm is focused on innovative delivery systems, with a notable emphasis on drugs that consider both efficacy and patient comfort. Their proprietary technology, PharmFilm®, is a key asset in their development strategy.
About Aquestive Therapeutics
Aquestive Therapeutics is committed to revolutionizing the pharmaceutical landscape by advancing medicines that significantly better the lives of patients. The company specializes in the development of orally administered therapeutic products that facilitate the delivery of complex molecules, offering new alternatives to standard care methods that can often be invasive and inconvenient. Currently, they market four commercialized products through partnerships in the U.S. and globally. In addition to their existing products, Aquestive is also advancing a late-stage proprietary candidate targeting severe allergic reactions and a topical gel aimed at various dermatological conditions, including alopecia areata.
Investor Relations Contact Information
For further inquiries, investors can reach out to Brian Korb at astr partners via email at brian.korb@astrpartners.com.
Frequently Asked Questions
What is the purpose of the recent $85 million offering by Aquestive?
The offering aims to advance the launch and commercialization of Anaphylm™ (epinephrine) Sublingual Film, intended for severe allergic reactions, plus other corporate purposes.
Who managed the underwritten offering?
RTW Investments, LP led the offering with participation from other notable investment firms including Samsara BioCapital and EcoR1 Capital.
What technology does Aquestive utilize for their products?
Aquestive leverages its proprietary PharmFilm® technology to develop innovative drug delivery systems that improve patient experience.
What is the significance of FDA approval for Aquestive's offerings?
FDA approval is critical for the commercialization of Anaphylm™ and ensures the safety and efficacy of their therapeutic innovations.
How can investors contact Aquestive for more information?
Investors can reach Brian Korb at astr partners through email at brian.korb@astrpartners.com for inquiries and further information.
